Monograph Details

Ob/Gyn > Menopause and HRT
PREMPRO 0.625mg/2.5mg
Manufacturer
Wyeth Pharmaceuticals
Legal Classification
Rx
Pharmacological Class
Estrogen + progestin.
Generic Name
Conjugated estrogens 0.625mg, medroxyprogesterone acetate 2.5mg; tabs.
Also
PREMPRO 0.3mg/1.5mg
PREMPRO 0.45mg/1.5mg
PREMPRO 0.625mg/5mg
Indications
In women with an intact uterus: moderate to severe vasomotor symptoms associated with menopause; vulvar and vaginal atrophy; osteoporosis prevention (consider alternative treatments).
Children
Not applicable.
Adults
Initially 0.3mg/1.5mg once daily; consider dose increase if bleeding is problematic; periodically reassess need for higher dose.
Contraindications
Breast or estrogen-dependent carcinoma. Undiagnosed abnormal genital bleeding. Pulmonary embolism/DVT (active or history of). Arterial thromboembolism (eg, stroke, MI; active or recent). Hepatic impairment. Missed abortion. Pregnancy (Cat.X).
Precautions
Not for prevention of cardiovascular disease. Use for shortest duration consistent with treatment goals and risks. Reevaluate periodically. Gallbladder disease. Hypercalcemia in breast cancer or bone metastases. Conditions aggravated by fluid retention. Familial hyperlipidemia. Hypercoagulation states. Do initial complete physical and repeat at least yearly (include BP, PAP smear, mammogram). Discontinue if cardiovascular events or visual abnormalities occur or are suspected. May interfere with lab tests; see literature. Nursing mothers: not recommended.
Adverse Reactions
See literature. Increased risk of cardiovascular events, breast cancer (in prolonged use). GI upset, pain, cramps, hepatic impairment, mastodynia, breakthrough bleeding, altered cervical secretion, vaginal infections, edema, worsening of porphyria, headache, migraine, dizziness, dementia, changes in vision, intolerance to contact lenses, muscle spasms, hair loss, weight or libido changes.
How Supplied
EZ-Dial dispensers—3
Additional Resources
Related Prescribing Note